INTRODUCTION
Differentiated thyroid carcinoma (DTC), accounting for more than 95% of cases of thyroid cancer, is the most common malignancy in the endocrine system. Worldwide increasing incidence of thyroid cancer has drawn more attention to multiple therapies (1) . Despite rising incidence, the mortality from thyroid cancer has not changed significantly over the past five decades, which closely correlated to its reliable treatment procedures (2) . Currently, the treatment process of DTC generally consists of three steps: total or partial thyroidectomy, followed by radioiodine (RAI, iodine-131 [131I]) therapy to clear residual thyroid tissue and thyroid-stimulating hormone (TSH) suppression therapy with levothyroxine, DOI:10.4158/EP-2019-0398 © 2019 AACE. except for American Thyroid Association (ATA) low-risk DTC patients, for whom RAI remnant ablation is not routinely recommended (3) .
RAI therapy is an adjuvant therapy of surgery to clear residual thyroid tissue and a vital approach for patients with lymph node metastases to clear both residual thyroid and metastatic lymph nodes, which has been used in thyroid cancer for more than 70 years (4) . It is also known as RAI remnant thyroid ablation when used for clearing residual thyroid post-surgery and is recommended for ATA high-risk DTC patients and some intermediate-risk patients. RAI therapy is considered a mature adjuvant therapy to improve survival rates or reduce recurrent rate according to previous researches in the above two types of patients (5) (6) (7) (8) . However, due to the close anatomic relationship between thyroid and parathyroid glands: the latter is located on the surface of the former (9), the effect of RAI therapy on parathyroid function should be carefully considered. But views of previous studies remained controversial. Some studies and cases have reported hyperparathyroidism after RAI therapy (10) (11) (12) (13) , and some studies found hypoparathyroidism and electrolyte disorders (such as hypocalcemia and hypophosphatemia) caused by radioiodine (14) (15) (16) (17) (18) . Some prospective studies found that radiation therapy had no significant effect on parathyroid function (19, 20) . Therefore, this study aimed to determine whether RAI therapy following a thyroidectomy resulted in a decrease of the parathyroid function.
This study aimed to determine the effect of RAI therapy following a DOI:10.4158/EP-2019-0398 © 2019 AACE. thyroidectomy on the parathyroid function by analyzing changes of parathyroid hormone (PTH), serum calcium, phosphorus, and magnesium.
METHOD

Patients
We retrospectively studied 81 consecutive patients with pathologically confirmed DTC who received RAI remnant ablation after a total or subtotal thyroidectomy at Renji Hospital, Shanghai, China, from January 2016 to May 2018.
The study was approved by the ethics committee of Renji Hospital. We included patients who were initially treated with 131I between the ages of 18 and 75 years. Tumor's TNM staging was based on the initial surgical specimens. TNM classification was made through the original pathology report according to the 8th edition of the AJCC/TNM staging system for thyroid cancer (21) .
Exclusion criteria were as follows: thyroid secondary tumor; pregnancy, infection, autoimmune diseases, or other organ dysfunctions; undergoing 131I therapy before; parathyroid glands injury or parathyroid transplantation; parathyroid glands removal during surgery; recently taking calcium or vitamin D; found hypocalcemia (serum calcium < 2.03 mmol/L), hypoparathyroidism or PTH < 12 pg/ml before RAI therapy. All patients were informed and agreed to join the study.
We finally included 56 females and 25 males, aged 20~70 years, with an DOI:10.4158/EP-2019-0398 © 2019 AACE. average age of 43.69 ± 12.13 years. Among all cases, 78 were papillary thyroid cancer (PTC), 3 were follicular thyroid cancer (FTC). The T stage and N stage of all cases were listed in Table 1 .
Treatment Methods
Before starting 131I treatment, all patients stopped taking levothyroxine for four weeks. They were also instructed to follow a low-iodine diet and to stop any drugs containing iodine. We ensured that thyroid-stimulating hormone (TSH) of each patient increased to 30 mIU/L or more. All patients were treated with an activity of 3.7GBq (or 100mCi) 131I for the ablation of residual thyroid tissue. The drugs were administered via the 131I automatic filling instruments of Hicheer Sci-Tec Co., Ltd. (Beijing, China). After administration of 131I, patients were isolated and monitored in the nuclear medicine ward for 72 hours. The treatment was basically guided with ATA risk stratification but other risk estimates were also considered (22) . Risks and benefits of each patient were carefully evaluated and the individual choice was respected to the greatest extent. Thyroid 131I uptake rate was detected before treatment and the patients whose remnant uptake > 10% were excluded. All patients underwent an ultrasound and Technetium-99m (99mTc)-pertechnetate thyroid scan (99mTc thyroid scan) before RAI therapy to assess the residual sizes of thyroid and 131I wholebody scan (131I WBS) at the third day after the administration of radioiodine to assess the iodine uptake ability. If the results of WBS showed no abnormal DOI:10.4158/EP-2019-0398 © 2019 AACE. radioiodine uptake in the whole body and the thyroglobulin (TG) of patients continued to be <1 ng/ml (22) , the treatment was considered successful.
Parathyroid and Thyroid Function Measurement
Fasting blood samples were collected on the day before admission to evaluate thyroid function, parathyroid function, liver, and kidney function and so on, including free tri-iodothyronine (FT3), free thyroxine (FT4), TSH, TG, PTH, serum calcium, phosphorus and magnesium. One month and three months later, all the above markers were checked again, then the changes were analyzed.
The reference ranges were as follows: FT3 (3.5-6.5 pmol/L), FT4 (11. The equipment used for FT3, FT4 and TSH measurement was ADVIA Centaur XP Immunoassay System (Siemens co., Germany). PTH was assessed by Immulite 1000 Immunoassay System (Siemens co., Germany), and TG was assessed by 6000 analyzer (Roche Diagnostics, Switzerland). Discovery NM/CT 670 (GE Healthcare, USA) was used for 99mTc thyroid scan and 131I WBS. The differences between all batches and within batches were in the range of laboratory quality control, and the fluctuations < 5%.
Grouping and Statistical Analysis
The patients were divided into female group and male group according to the sex, and divided into < 45 group and ≥ 45 group according to the age. Sizes of the residual thyroid were evaluated by visual and semiquantitative analysis of postoperative 99mTc thyroid scan images and 131I WBS images, which was divided into three levels based on the uptake of 99mTc or 131I and then scored with 0 to 3 points: 0 for no uptake in the bed of thyroid glands; 1 for faint uptake; 2 for moderate uptake; 3 for intense uptake. The groups of T and N stage were divided on the basis of TNM classification in the guideline of American Thyroid Association (22) .
The data were analyzed using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.0 software (GraphPad Software Inc., La Jolla, CA, USA).
One-way ANOVA was performed to analyze continuous data, including PTH, serum calcium, phosphorus, magnesium, FT3, and FT4 levels before and after treatment, which were presented as mean ± standard deviation (SD). Rank sum tests were performed to analyze the non-continuous variables, including TSH and TG levels before and after treatment. The χ2 tests were used for the comparison of PTH changes between different subgroups, such as sex, age, scores of 99mTc thyroid scan, scores of 131I WBS, T stage and N stage. P < 0.05 was considered statistically significant. We included a total of 81 patients. Patients' characteristics are displayed in Table 1 .
RESULTS
Characteristics of Patients
Comparison of Parathyroid Function
We compared the PTH, serum calcium, serum phosphorus, and magnesium one day before RAI therapy, one month and three months after treatment. Table   2 displays the results of one-way ANOVA. There were no significant differences in PTH, serum calcium and phosphorus between three time points (P > 0.05). For magnesium level, the result of ANOVA showed P < 0.05, then Student-Newman-Keuls (SNK) test was used for the analysis between three time points. It found no significant difference between one month post group and three months post group (P > 0.05). That is to say, serum magnesium elevated in the first month after treatment and remained until three months after. And all patients' calcitonin levels were below 2 pg/ml from pre-treatment to three months after. Among 81 patients, only five patients' PTH declined below standard reference value three months after treatment, accounting for 6.2%.
The results of χ2 tests for subgroups are shown in Table 3 . Pearson χ2 tests were used to compare differences of PTH changes between different gender groups and age groups. There were no significant differences between males and females (P = 0.779), between < 45 years old and ≥ 45 years old (P = 138). Fisher's Exact Test was used for analyzing relations of PTH changes and different scores of 99mTc thyroid scan, scores of 131I WBS, T stage and N stage. The results showed that the PTH changes was independent of these factors (P > 0.05). The grading criteria of 99mTc thyroid scan and 131I WBS are detailed in Table 4 and typical images are given in Figure 1 .
Changes in Thyroid Function Before and After Treatment
As shown in Table 5 , the FT3 and FT4 levels were increased and the TSH level was decreased due to the resumption of levothyroxine (P < 0.05). The TG level was also decreased (P < 0.05).
DISCUSSION
The ATA postoperative risk stratification is generally used for RAI treatment decisions. RAI remnant ablation is not routinely recommended for ATA low-risk DTC patients after thyroidectomy, but for high-risk and some of intermediate-risk patients, it is routinely recommended (3). To avoid recurrence and distant metastasis, post-surgery RAI therapy is necessary for most intermediated-risk and high-risk DTC patients in clinical practice. The ablation function of 131I mainly depends on β-rays, with an average range of 0.4 mm in soft tissue, which can destroy thyroid follicular cells without hurting other normal tissues (23) . The parathyroid glands are located next to the thyroid glands, so it might be an issue of concern that if RAI treatment will impair parathyroid glands. It was first reported in 1975 that external beam radiation could cause hyperparathyroidism (24) . In this study, we included the DTC patients treated with the same dose of 131I to avoid the effect of the radiation dose on the results. The results of the present study show that there were no significant differences in PTH, serum calcium and phosphorus from pre-treatment to one month post-treatment and three months post-treatment, though the magnesium level slightly increased after RAI therapy.
Previous studies found that magnesium levels declined commonly after thyroidectomy, and magnesium levels trended to influenced by calcium levels postoperatively (28) (29) (30) . The rise of magnesium levels after RAI therapy in our study might be a cause of post-surgery recovery. Only 6.2% of patients had a decrease in PTH below 12pg/ml, among whom only one had hypocalcemia with a calcium level of 1.87 mmol/L. No patients showed the manifestation of hypoparathyroidism within 3 months after RAI treatment in this study. Meanwhile, our findings show that a 100 mCi dose of 131I administered was safe for the parathyroid function. We also analyzed the relations between PTH changes of each patient and clinical factors. PTH changes were not significantly related to gender, age, size of residual thyroid, iodine uptake ability of thyroid and TNM stages. Our follow-up endpoint was set at three months after treatment. This a regular return visit time, but longer follow-up is needed to find long-term effects.
In this study, the TG levels were significantly decreased, indicating the satisfactory therapeutic effect of RAI therapy.
However, in-depth subgroup analysis could not be done because of the limitation of sample size. According to the practical clinical situation, patients often take different doses of 131I and sometimes are treated more than once. So, larger samples and more specific prospective researches are expected in the future, such as the effects of different doses and times of 131I administration on the parathyroid glands.
CONCLUSION
In conclusion, the results of this study have confirmed the safety of RAI therapy to parathyroid grand. RAI therapy did not significantly affect the parathyroid function.
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